BRAF and neoplasm: Therefore, experiments are underway to investigate whether the combined administration of CD244-deficient macrophages with targeted therapies, whose efficacy are influenced by the tumor immune microenvironment, such as BRAF inhibitors, can amplify anti-tumor immune responses through the enhancement of tumor antigen-specific CD8 T cell responses.